Secretary John Kerry To Lead Galvanize Climate Solutions As Co-Executive Chair

Secretary John Kerry Joins Galvanize Climate Solutions As Co-Executive Chair. The 68th U.S. Secretary of State and former U.S. Special Presidential Envoy for Climate joins investment firm to scale commercially competitive climate solutions

Galvanize Climate Solutions (“Galvanize”), an investment firm focused on generating long-term value from the energy transition, recently announced the appointment of Secretary John Kerry as co-executive chair. He will be working closely alongside co-executive chairs Tom Steyer and Katie Hall combining the insights and experience of the world’s leading climate statesman with the firm’s blue-chip investment […]

MaxLinear With Its Latest MaxAI Use Case Boosts Overall Wi-Fi Experience And Curb Budget MSOs

MaxLinear Enhances Overall Wi-Fi Experience and Lowers Costs for MSOs with New MaxAI™ Use Case Aware AI/ML Framework. MaxAI is a robust, use case aware, native-ML, technology framework, designed to enhance and improve the quality of service across communication links, improve overall end-to-end user experience, and lower support costs

MaxLinear, Inc. (Nasdaq: MXL), a global leader in broadband access and gateway solutions, recently unveiled MaxAI™, a groundbreaking hardware-optimized, use-case aware, native-ML technology framework designed to provide enhanced user experience, improve quality of service (QoS), and lower support costs for Multiple System Operators (MSOs). According to Industry sources, with ubiquitous Wi-Fi across the globe, hundreds […]

GE Healthcare Announces Phase-I Results For Macrocyclic Manganese-Based MRI Agent

GE Healthcare Announces Phase-I Results For Macrocyclic Manganese-Based MRI Agent. The clinical trial program demonstrates GE HealthCare’s commitment to innovation in contrast media and to building a portfolio of MRI imaging agents to address radiologists’ needs for their patients.

GE HealthCare (Nasdaq: GEHC) has recently announced the completion of its Phase I clinical development program for a first-of-its-kind manganese-based macrocyclic magnetic resonance imaging (MRI) contrast agent. According to Industry sources, the outcome, which will be utilized to aid ongoing clinical development, concluded that in a first-in-human study, this manganese-based contrast agent was well tolerated […]